参芪扶正联合化疗对乳腺癌患者血清TNF-α,CCL18及IL-6表达水平的影响  

Impact of Shenqifuzheng combination chemotherapy on the expression levels of TNF-α,CCL18 and IL-6 in the serum of breast cancer patients

作　　者：漆起贵[1] 岳莉[1] 王莹[1] 李华[1] 高宇[1] 许燕艳[1] 王芳[1] 张微[1] 

机构地区：[1]辽宁医学院,锦州121001

出　　处：《中国新药杂志》2013年第10期1196-1201,共6页Chinese Journal of New Drugs

基　　金：中国临床肿瘤学科学基金(丽珠中医药肿瘤研究基金Y-L2011-001);CSCO-金橄榄香烯肿瘤学研究生助学基金(Z-2011-004)

摘　　要：目的:探讨TNF-α,CCL18及IL-6在乳腺癌患者血清中表达的临床意义及3个因子的相关性,并评估参芪扶正注射液联合化疗在治疗乳腺癌患者过程中的价值。方法:采用ELISA法检测46例乳腺癌患者,23例乳腺良性病和19例健康体检者血清TNF-α,CCL18及IL-6水平,并比较对照组和实验组用药前后血清表达水平的变化和疗效。结果:TNF-α,CCL18及IL-6在健康体检者组,乳腺良性病组和乳腺癌组血清中表达水平依次升高,差异有统计学意义(均P<0.05);TNF-α,CCL18及IL-6的表达水平与淋巴结转移和ER状态相关,而与PR,HER-2,肿瘤大小和病理类型等无关;乳腺癌患者血清中TNF-α,CCL18及IL-6表达水平呈正相关;参芪扶正注射液联合化疗能降低三者表达水平,差异具有统计学意义(P<0.05);实验组治疗有效率高于对照组。结论:高水平的TNF-α,CCL18及IL-6可能协同促进了乳腺癌的发生和发展,检测这3个因子的表达有助于乳腺良恶性的鉴别;参芪扶正注射液联合化疗能保护骨髓和减轻化疗毒副作用,并能降低三者血清表达水平,在调节乳腺癌患者免疫力方面起着积极的作用。Objective： To explore the expression levels and clinical significance of TNF-α, CCL18 and IL- 6 in the serum of breast cancer patients, analyze the correlation among them and assess the value of Shenqifuzheng injection combination chemotherapy in the treatment of breast cancer patients. Methods ： Elisa method was used to detect the expressions of TNF-α, CCL18 and IL-6 in 19 healthy subjects, 23 benign breast disease patients and 46 breast cancer patients before and after treatment. The expression levels of TNF-α, CCL18 and IL-6 and the efficacy of the drug were compared between the control and experimental group. Results： The serum expression levels of TNF-α, CCL18 and IL-6 in breast cancer patients were significantly higher than those in the healthy subjects and benign breast disease patients （P 〈0.05）. The expressions of TNF-α, CCL18 and IL-6 were correlated to lymph node metastasis and ER status,but not to PR, HER-2,tumor size and pathological grade, etc. The expression levels of TNF-α, CCL18 and IL-6 in breast cancer patients were positively correlated. The post-treatment expression lev- els of TNF-α, CCL18 and IL-6 in the experimental group were significantly lower than those before treatment （P 〈0.05）. The effective rate of the experimental group was higher than the control group. Conclusion： High levels of TNF-alpha, CCL18 and IL-6 may synergistically promote the occurrence and development of breast cancer. Detec- ting the expression may help identify benign and malignant breast diseases. Shenqifuzheng injection plays an active role in regulating the immune system of patients with breast cancer： it can protect the bone marrow, reduce the side effects of chemotherapy, and reduce the expression levels of the three immunomodulatory factors.

关 键 词：乳腺癌 肿瘤坏死因子 趋化因子配体18 白介素6 参芪扶正注射液 

分 类 号：R932[医药卫生—生药学]